Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Rev. invest. clín ; 73(2): 94-99, Mar.-Apr. 2021. tab, graf
Artículo en Inglés | LILACS-Express | LILACS | ID: biblio-1251869

RESUMEN

ABSTRACT Background: The biology of some hematological diseases varies among different populations. No previous studies have evaluated the clinical behavior of mantle cell lymphoma (MCL) in México. Objective and Methods: This is a retrospective review of MCL cases seen in Mexico from January 2003 to June 2020. A total of 12 cases were identified. Results: There were nine males and three females; median age was 56 years. Eight patients had a high MCL international prognostic index score, one was intermediate, and three were low. Five patients had circulating malignant monoclonal cells. Initial treatment included rituximab, cyclophosphamide, daunorubicin, vincristine, and prednisone (R-CHOP) and CHOP. Subsequent treatment included hematopoietic stem cell transplantation in five patients; two were given maintenance therapy. Splenectomy was done in four patients. Median overall survival (OS) for all the patients has not been reached and exceeds 162 mos: OS at 162 mos was 56%. Achieving a complete remission (CR) after the first treatment was a significant prognostic factor, with a median OS exceeding 141 mos in patients achieving CR, and 16 mos among those not achieving CR (p = 0.0006). Conclusion: Some of MCL patients in Mexico have an indolent clinical course, particularly patients who achieve a CR to initial treatment and who undergo splenectomy.

2.
Rev. invest. clín ; 72(3): 159-164, May.-Jun. 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1251850

RESUMEN

ABSTRACT Background: The ideal treatment of coronavirus disease (COVID)-19 has yet to be defined, but convalescent plasma (CoPla) has been successfully employed. Objective: The objective of the study was to study the safety and outcomes of the administration of CoPla to individuals with severe COVID-19 in an academic medical center. Methods: Ten patients were prospectively treated with plasma from COVID-19 convalescent donors. Results: Over 8 days, the sequential organ failure assessment score dropped significantly in all patients, from 3 to 1.5 (p = 0.014); the Kirby index (PaO2/FiO2) score increased from 124 to 255, (p < 0.0001), body temperature decreased significantly from 38.1 to 36.9°C (p = 0.0058), and ferritin levels also dropped significantly from 1736.6 to 1061.8 ng/ml (p = 0.0001). Chest X-rays improved in 7/10 cases and in 6/10, computerized tomography scans also revealed improvement of the lung injury. Decreases in C-reactive protein and D-dimer levels were also observed. Three of five patients on mechanical ventilation support could be extubated, nine were transferred to conventional hospital floors, and six were sent home; two patients died. The administration of CoPla had no side effects and the 24-day overall survival was 77%. Conclusions: Although other treatments were also administered to the patients and as a result data are difficult to interpret, it seems that the addition of CoPla improved pulmonary function.


Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Adulto Joven , Neumonía Viral/terapia , Infecciones por Coronavirus/terapia , Betacoronavirus/aislamiento & purificación , Betacoronavirus/inmunología , Plasma , Índice de Severidad de la Enfermedad , Temperatura Corporal , Proteína C-Reactiva/análisis , Biomarcadores , Tomografía Computarizada por Rayos X , Proyectos Piloto , Convalecencia , Inmunización Pasiva , Resultado del Tratamiento , Infecciones por Coronavirus/tratamiento farmacológico , Infecciones por Coronavirus/diagnóstico por imagen , Terapia Combinada , Estimación de Kaplan-Meier , Ferritinas/sangre , Pandemias , SARS-CoV-2 , COVID-19 , Pulmón/diagnóstico por imagen , Anticuerpos Antivirales/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA